Serial PET MPI in Patients Undergoing Cancer Treatment

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT05913999
Status
Enrolling By Invitation

Conditions

  • Cancer
  • Chemotherapeutic Toxicity
  • Coronary Artery Disease
  • Coronary Microvascular Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.

Key Dates

Start date
Jun 1, 2023
Status verified
Aug 2025
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Anthracycline
    Patients undergoing chemotherapy with an anthracycline-containing regimen.
  • Arm: VEGF Inhibitor
    Patients undergoing chemotherapy with a vascular endothelial growth factor (VEGF) inhibitor-containing regimen.
  • Arm: Immune Checkpoint Inhibitor
    Patients undergoing chemotherapy with an immune check point inhibitor-containing regimen.

Primary Outcome Measure

PET myocardial perfusion imaging (MPI). [ Time Frame: Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
West Los Angeles VA Medical CenterLos AngelesCalifornia90073-

Find similar trials in Los Angeles, CA

By research site
West Los Angeles VA Medical Center· Los Angeles, CA

Related Studies